IP Library Granted Patent US 8,829,219
Granted Patent B2
US 8,829,219 · App. 13/735,635 · Granted Sep 9, 2014

Olefin metathesis catalysts and related methods

Inventors: Adam S. Hock (Cambridge, MA); Richard R. Schrock (Winchester, MA)
Assignee: Massachusetts Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,829,219
App. No.
13/735,635
Granted
Sep 9, 2014
Kind
B2
Abstract

The present invention provides methods for the synthesis of catalysts and precursors thereof. Methods of the invention may comprise combining a catalyst precursor and at least one ligand to generate a catalytically active species, often under mild conditions and in high yields. In some cases, a wide variety of catalysts may be synthesized from a single catalyst precursor. Methods of the invention may also include the preparation of catalysts which, under reaction conditions known in the art, may have been difficult or impossible to prepare and/or isolate due to, for example, steric crowding at the metal center. The present invention also provides catalyst compositions, and precursors thereof, which may be useful in various chemical reactions including olefin metathesis. In some cases, methods of the invention may reduce the number of synthetic and purification steps required to produce catalysts and/or other reaction products, as well as reducing time, cost, and waste production.

Claims (84)

1. A metal complex of formula:

wherein:

M is Mo or W;

R 1 is an optionally substituted aryl or heteroaryl;

R 2 and R 3 can be the same or different and are hydrogen, or an optionally substituted group selected from alkyl, heteroalkyl, aryl, or heteroaryl; and

R 6 and R 7 can be the same or different and are an optionally substituted group selected from heteroalkyl or heteroaryl;

at least one of R 6 and R 7 is an oxygen-containing ligand; and

wherein:

R 6 and R 7 are not joined together to form a bidentate ligand with respect to M; and

said compound is other than:

M(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](OtBu) 2 ,

M(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCEt 3 ) 2 ,

W(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCMe 2 Ph) 2 ,

M(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )][OCMe(CF 3 ) 2 ] 2 ,

M(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )][OC(CF 3 ) 2 (C 2 F 7 ] 2 ,

M(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](OtBu) 2 ,

M(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCEt 3 ) 2 ,

W(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCMe 2 Ph) 2 ,

M(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )][OCMe(CF 3 ) 2 ] 2 ,

M(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )][OC(CF 3 ) 2 (C 2 F 7 )] 2 ,

M(CH-t-Bu)[N(2,6-Me 2 C 6 H 3 )](OtBu) 2 ,

M(CH-t-Bu)[N(2,6-Me 2 C 6 H 3 )][OCMe(CF 3 ) 2 ] 2 ,

M(CH-t-Bu)[N(2,6-Me 2 C 6 H 3 )][OC(CF 3 ) 2 (C 2 F 7 )] 2 ,

M(CHCMe 2 Ph)[N(2,6-Me 2 C 6 H 3 )](OtBu) 2 ,

M(CHCMe 2 Ph)[N(2,6-Me 2 C 6 H 3 )][OCMe(CF 3 ) 2 ] 2 ,

M(CHCMe 2 Ph)[N(2,6-Me 2 C 6 H 3 )][OC(CF 3 ) 2 (C 2 F 7 ] 2 ,

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCHMe 2 ) 2 ,

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCMe 2 tBu) 2 ,

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](O-adamantyl) 2 ,

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCMe 2 CF 3 ) 2 ,

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )][OC(CF 3 ) 2 ],

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )][OCH(CF 3 ) 3 ],

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCHMe 2 ) 2 ,

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCMe 2 tBu) 2 ,

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](O-adamantyl) 2 ,

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](OCMe 2 CF 3 ) 2 ,

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )][OCH(CF 3 ) 2 ],

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )][OC(CF 3 ) 3 ],

Mo(CH-t-Bu)[N(2,6-Me 2 C 6 H 3 )](OCMe 2 CF 2 ) 2 ,

Mo(CHCMe 2 Ph)[N(2,6-Me 2 C 6 H 3 )](OCMe 2 CF 3 ) 2 ,

Mo(CH-t-Bu)[N(2-tBuC 6 H 3 )](OtBu) 2 ,

Mo(CH-t-Bu)[N(2-tBuC 6 H 3 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CH-t-Bu)[N(2-tBuC 6 H 3 )](O-adamantyl) 2 ,

Mo(CHCMe 2 Ph)[N(2-tBuC 6 H 3 )](OtBu) 2 ,

Mo(CHCMe 2 Ph)[N(2-tBuC 6 H 3 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CHCMe 2 Ph)[N(2-tBuC 6 H 3 )](O-adamantyl) 2 ,

Mo(CH-t-Bu)[N(2,6-(i-Pr) 2 -4-bromoC 6 H 2 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 -4-bromoC 6 H 2 )][OCMe(CF) 2 ] 2 ,

Mo(CH-t-Bu)[N(2-trifluoromethylC 6 H 4 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CHCMe 2 Ph)[N(2-trifluoromethylC 6 H 4 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CH-t-Bu)[N(2-phenylC 6 H 4 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CHCMe 2 Ph)[N(2-phenylC 6 H 4 )][OCMe(CF 2 ) 2 ] 2 ,

Mo(CH-t-Bu)[N(2-isopropylC 6 H 4 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CHCMe 2 Ph)[N(2-isopropylC 6 H 4 )][OCMe(CF 2 ) 2 ] 2 ,

W(CHPh 2 )[N(2-isopropylC 6 H 1 )][OCMe(CF 3 ) 2 ] 2 ,

Mo(CHSiMe 2 )[N(2,6-(i-Pr) 2 C 6 H 3 )][OCMe(CF 2 ) 2 ] 2 ,

Mo(CH 2 )[N(2,6-(i-Pr) 2 C 6 H 3 )](OtBu) 2 ,

M(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )][O-2,6-(i-Pr) 2 C 6 H 3 ] 2 ,

M(CH-t-Bu)[N(2,6-(i-Pr) 2 C 6 H 3 )](O-2-t-BuC 6 H 4 ) 2 ,

M(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )][O-2,6-(i-Pr) 2 C 6 H 3 ] 2 ,

M(CHCMe 2 Ph)[N(2,6-(i-Pr) 2 C 6 H 3 )](O-2-t-BuC 6 H 4 ) 2 ,

M(CH-t-Bu)[N(2,6-Me 2 C 6 H 3 )][O-2,6-(i-Pr) 2 C 6 H 3 ] 2 ,

Mo(CH-t-Bu)[N(2,6-Me 2 C 6 H 3 )](OC 6 F 5 ) 2 ,

M(CHCMe 2 Ph)[N(2,6-Me 2 C 6 H 3 )][O-2,6-(i-Pr) 2 C 6 H 3 ] 2 ,

Mo(CHCMe 2 Ph)[N(2,6-Me 2 C 6 H 3 )](OC 6 F 5 ) 2 ,

Mo(CH-t-Bu)[N(2-t-BuC 6 H 4 )][O-2,6-(i-Pr) 2 C 6 H 3 ] 2 , and

Mo(CHCMe 2 Ph)[N(2-t-BuC 6 H 4 )](OC 6 F 5 ) 2 .

2. The compound according to claim 1 , wherein each of R 6 and R 7 is an oxygen-containing ligand.

3. The compound according to claim 2 , wherein the oxygen-containing ligand coordinates M via an oxygen atom.

4. The compound according to claim 3 , wherein R 1 is substituted aryl.

5. The compound according to claim 3 , wherein R 1 is a monosubstituted aryl, 2,6-disubstituted aryl, or 2,4,6-trisubstituted aryl.

6. The compound according to claim 3 , wherein one of R 2 and R 3 is hydrogen and the other of R 2 and R 3 is an optionally substituted group selected from alkyl, heteroalkyl, aryl, or heteroaryl.

7. The compound according to claim 3 , wherein:

M is Mo;

R 1 is substituted aryl;

R 2 is optionally substituted alkyl; and

R 3 is hydrogen.

8. The compound according to claim 3 , wherein:

M is W;

R 1 is substituted aryl;

R 2 is optionally substituted alkyl; and

R 3 is hydrogen.

9. The compound according to claim 3 , wherein the oxygen-containing ligand is chiral.

10. The compound according to claim 1 , wherein R 6 and R 7 can be the same or different and are optionally substituted heteroaryl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2014
From: HOCK, ADAM S.; SCHROCK, RICHARD R.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 032007/0970 →
Continuity (3)
Continuation 13033472 · Feb 23, 2011
Continuation 11603951 · Nov 22, 2006
Related Publication 20130281706A1 · Oct 24, 2013